Journal of Clinical Oncology NOVEMBER 24, 2021

Nivolumab plus Ipilimumab or Nivolumab Alone Versus Ipilimumab Alone in Advanced Melanoma (CheckMate-067)

Jedd D. Wolchok, Vanna Chiarion-Sileni, René Gonzalez, et al.

Bottom Line

In patients with previously untreated advanced melanoma, the combination of nivolumab and ipilimumab, as well as nivolumab monotherapy, demonstrated durable, superior long-term overall survival compared to ipilimumab alone.

Key Findings

1. At a minimum follow-up of 6.5 years, the median overall survival (OS) was 72.1 months for the nivolumab plus ipilimumab group, 36.9 months for the nivolumab-alone group, and 19.9 months for the ipilimumab-alone group.

2. The 6.5-year overall survival rates were 49% in the combination group, 42% in the nivolumab-alone group, and 23% in the ipilimumab-alone group.

3. Melanoma-specific survival was significantly improved with combination therapy, with the median not reached for the combination group, compared to 58.7 months for nivolumab alone and 21.9 months for ipilimumab alone.

4. The combination of nivolumab and ipilimumab resulted in a higher incidence of Grade 3/4 treatment-related adverse events (59%) compared to nivolumab alone (24%) and ipilimumab alone (28%), but no new safety signals were identified in long-term follow-up.

Study Design

Design

RCT

Double-Blind

Sample

945

Patients

Duration

6.5 yr

Median

Setting

Multicenter, International

Population Adult patients with previously untreated, unresectable stage III or stage IV melanoma.

Intervention Nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) every 3 weeks for four doses, followed by nivolumab (3 mg/kg) every 2 weeks.

Comparator Nivolumab (3 mg/kg) every 2 weeks (plus placebo) OR ipilimumab (3 mg/kg) every 3 weeks for four doses (plus placebo).

Outcome Overall survival and progression-free survival.

Study Limitations

• The study was not formally powered to compare the combination of nivolumab plus ipilimumab directly against nivolumab monotherapy, rendering those comparisons descriptive rather than confirmatory.

• The trial involved patients primarily enrolled before the modern era of personalized medicine in melanoma, which may influence generalizability to contemporary clinical practice incorporating other targeted therapies.

• The significant toxicity associated with the combination regimen requires careful clinical management and patient selection, which may not be reflected in standard clinical practice settings.

Clinical Significance

The CheckMate-067 trial established nivolumab plus ipilimumab as a benchmark for first-line therapy in advanced melanoma, demonstrating that immune checkpoint inhibition can achieve long-term, potentially curative-intent survival outcomes in a disease previously characterized by a dismal prognosis.

Historical Context

Prior to 2011, advanced melanoma was associated with a median survival of approximately 7 months. The introduction of the anti-CTLA-4 agent ipilimumab, followed by anti-PD-1 agents like nivolumab, fundamentally shifted the paradigm of treatment, with CheckMate-067 providing the definitive longitudinal evidence of survival plateaus and durable clinical control.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Explain the synergistic mechanism of action behind combining a CTLA-4 inhibitor like ipilimumab with a PD-1 inhibitor like nivolumab in the context of the cancer-immunity cycle.

Key Response

Ipilimumab (anti-CTLA-4) acts primarily during the 'priming phase' in secondary lymphoid organs by promoting T-cell activation and proliferation. Nivolumab (anti-PD-1) acts during the 'effector phase' within the tumor microenvironment by reversing T-cell exhaustion. Together, they address two distinct checkpoints, increasing both the quantity and the functional quality of the anti-tumor immune response.

Resident

In the CheckMate-067 trial, the combination of nivolumab and ipilimumab showed superior survival but at the cost of significantly higher toxicity. What is the approximate rate of Grade 3/4 immune-related adverse events (irAEs) in the combination arm, and how does this affect frontline decision-making?

Key Response

The rate of Grade 3/4 irAEs in the combination arm was approximately 59%, compared to 21% for nivolumab monotherapy. Clinically, this requires a risk-benefit assessment: the combination is often favored in patients with high tumor burden, BRAF mutations, or asymptomatic brain metastases, whereas monotherapy may be preferred in patients with significant comorbidities or those who prioritize lower toxicity.

Fellow

Analyze the impact of BRAF mutation status on the long-term overall survival outcomes observed in CheckMate-067. Does the combination therapy provide a distinct advantage over nivolumab monotherapy in BRAF-mutant patients?

Key Response

Long-term data suggests that patients with BRAF-mutant melanoma derive a numerically higher benefit from the combination (median OS 72.1 months) compared to nivolumab monotherapy (median OS 55.4 months). In contrast, the difference between the combination and nivolumab alone is less pronounced in BRAF-wild-type patients, suggesting that BRAF status remains a critical factor in selecting the intensity of frontline immunotherapy.

Attending

With 6.5 years of follow-up showing a plateau in the survival curves, how should the 'treatment-free interval' and the data on patients who discontinued therapy due to toxicity influence your counseling of a newly diagnosed patient?

Key Response

The study demonstrated that many patients who discontinued the combination early due to toxicity still achieved durable, long-term responses without further treatment. This 'functional cure' concept is a major teaching point: early intense immune activation can lead to a self-sustaining immune memory. Counseling should emphasize that even if the drugs are stopped for toxicity, the anti-tumor effect often persists for years.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Critique the use of ipilimumab as the control arm in CheckMate-067 and discuss how the high rate of subsequent PD-1 inhibitor use in that arm (crossover) potentially confounds the Hazard Ratio (HR) for Overall Survival.

Key Response

At the time of study design, ipilimumab was the standard of care. However, as PD-1 inhibitors became available, approximately 66% of the ipilimumab arm received subsequent effective immunotherapy. This crossover likely leads to an underestimation of the survival benefit of frontline nivolumab-based regimens (dilution of the effect size), making the observed HRs conservative estimates of the true treatment benefit.

Journal Editor

While CheckMate-067 is the definitive study for this regimen, it was not formally powered to compare the nivolumab-ipilimumab combination directly against nivolumab monotherapy. As a reviewer, why is it critical to highlight this limitation in the discussion of long-term updates?

Key Response

The study's primary endpoints were comparing each experimental arm to ipilimumab alone. Because the trial wasn't powered for a head-to-head comparison between the combination and nivolumab monotherapy, any claims of superiority of the combo over nivo-alone remain descriptive rather than inferential. This prevents the over-interpretation of numerical differences that may not reach statistical significance if the trial had been designed differently.

Guideline Committee

Current NCCN and ASCO guidelines list both nivolumab-ipilimumab and nivolumab monotherapy as Category 1 options for first-line treatment. Based on the 6.5-year CheckMate-067 data, should the guidelines be updated to prioritize the combination in specific subgroups, such as PD-L1 negative patients?

Key Response

In patients with PD-L1 expression <1%, the combination showed a median OS of 49.1 months vs 39.1 months for nivolumab alone. While both remain recommended, the committee might consider 'preferring' the combination for PD-L1 negative or BRAF-mutant patients where the absolute survival delta is widest, while maintaining monotherapy as a preferred option for PD-L1 positive patients to minimize toxicity without compromising long-term survival.

Clinical Landscape

Noteworthy Related Trials

2010

MDX010-20

n = 676 · NEJM

Tested

Ipilimumab

Population

Patients with previously treated metastatic melanoma

Comparator

gp100 peptide vaccine

Endpoint

Overall survival

Key result: Ipilimumab, with or without a gp100 vaccine, improved overall survival compared to the vaccine alone.

2015

KEYNOTE-006

n = 834 · NEJM

Tested

Pembrolizumab

Population

Patients with advanced melanoma

Comparator

Ipilimumab

Endpoint

Progression-free survival and overall survival

Key result: Pembrolizumab significantly improved both progression-free survival and overall survival compared to ipilimumab.

2015

CheckMate-066

n = 418 · NEJM

Tested

Nivolumab

Population

Patients with previously untreated BRAF-wild-type advanced melanoma

Comparator

Dacarbazine

Endpoint

Overall survival

Key result: Nivolumab showed significantly higher overall survival rates compared to dacarbazine chemotherapy.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis